The Management of Cytokine Storm in COVID-19

Authors

  • Cleopas Martin Rumende Division of Respirology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital. Jakarta, Indonesia
  • Erwin C Susanto Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Truely P Sitorus Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Keywords:

cytokine storm, hyperinflammation, COVID-19

Abstract

Cytokine storm in COVID-19 infection is an excessive immune response to external stimuli where the pathogenesis is complex. The disease progresses rapidly and the mortality is high. Certain evidence shows that the severe deterioration of some patients has been closely related to the strong upregulation of cytokine production in SARS-Co-V2 induced pneumonia with an associated cytokine storm syndrome. Identification of existing approaved therapy with proven safety profile to treat hyperinflammation is critical unmet need in order to reduce COVID-19 associated mortality. To date, no specific therapeutic drugs are available to treat COVID-19 infection. Preliminary studies have shown that immune-modulatory or immune suppressive treatments might be considered as treatment choices for COVID-19, particularly in severe disease. This article review the pathogenesis and treatment strategies of COVID-19 virus-induced inflammatory storm in attempt to provide valuable medication guidance for clinical treatment.

Author Biography

Cleopas Martin Rumende, Division of Respirology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital. Jakarta, Indonesia

I am staff of Divisi Respirologi dan Penyakit Kritis, Dept. Ilmu Penyakit Dalam Universitas Indonesia, RSUPN.Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta INDONESIA

References

Clinical management of COVID-19. Interim Guidance. Geneva : World Health Organization; 2020.

Qing Ye, Bili Wang, Jianhua Mao. The pathogenesis and treatment of the cytokine storm in COVID-19. J Infect Dis. 2020. doi.org/10.1016/j.jinf.2020.03.037.

Mousavizadeh L, Ghasemi S, Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020. doi.org/10.1016/j.jmii.2020.03.022.

Singh VK, Mishra A, Singh S, Kumar P, Singh M, Jangannath C, Khan A. Emerging prevention and treatment strategies to control COVID-19. Pathogen. 2020;9;2-16.

Tufan A, Guler AA, Cerinic MM. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-30.

Felsenstein S, Herbert J, McNamara P, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020. doi.org/10.1016/j.clim.2020.108448.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Hearth Lung Transplant. 2020;39:405-7.

COVID-19: Pathogenesis, cytokine storm and therapeutic potensial of interferons. Cytokine Growth Factor Rev. 2020. doi.org/10.1016/j.cytogfr.2020.05.002.

Roche AG. Cytokines release syndrome, reviewing a new entity in the intensive care unit. Med Intensiva. 2019;43 (8):480-8.

Gupta KK, Khan MA, Singh SK. Constitutive inflammatory cytokines storm: A major threat to human health. J Interfer Cytokine Res. 2020;40 (1):1-5.

Instiaty, Darmayani I G A P. Marzuki JE, et al. Antiviral treatment of COVID-19: clinical pharmacology narrative review. Med J Indones. 2020.

Sanders JM, Monogue ML, JodlowskiTZ, Cutrell JB. Pharmacologic treatment for Coronavirus disease 2019 (COVID-19). JAMA. 2020;323:1824-36.

Delang L, Neyts J. Medical treatment options for COVID-19. Eur Heart J: Acute Cardiovas Care. 2020; 9: 209-14.

Murthy H. Cytokines release syndrome: Current perspectives. Immuno Targers Ther. 2019;8:43-52.

Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the cytokine storm in COVID-19: Therapeutic implication. Cardiorenal Med. Doi: 10.1159/000509483.

Cao W. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus disesase is 2019. Infect Dis Soc Am. 2020.

Xiaosheng Liu, Wei Cao, Taisheng Li. High-dose intravenous immunoglobulins in the treatment of sebere acute viral pneumonia: the known mechanism and clinical effect. Frontiers Immunology. Doi: 10.3389/fimm.2020.01660.

Chen L. Convalescent plasma as a potential therapy for COVID-19. Lancet. 2020; 0: 98-400.

Shen C. Treatment of 5 Critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020.

Al-Anazi KA, Al-Alnazi WK, Al-Jasser AM. Update on COVID-19 infections and the promising role of mesenchymal stem cell therapies in their management. 2020.

Downloads

Published

2020-10-04

How to Cite

Rumende, C. M., Susanto, E. C., & Sitorus, T. P. (2020). The Management of Cytokine Storm in COVID-19. Acta Medica Indonesiana, 52(3), 306. Retrieved from https://actamedindones.org/index.php/ijim/article/view/1580

Issue

Vol. 52 No. 3 (2020): Acta Medica Indonesiana

Section

CLINICAL PRACTICE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.